News Feed

NANETS Regional Education Sponsorship 2024

PMWC Presentation

Wren Laboratories Dr. Mark Kidd speaks at 2024 Precision Medicine World Conference

The Sounds of a Zebra – Symptoms of Neuroendocrine Cancer

NET November – Bringing Awareness to a Cancer that is Rare but on the Rise

Wren Laboratories’ new molecular diagnostic predicts patient response to Peptide Receptor Radionuclide Therapy with unprecedented accuracy

Smilow Cancer Hospital Closer to Free Ride Sponsor

Wren, NETest featured in GenomeWeb Article

Wren Laboratories Expands Flagship Molecular Cancer Diagnostic NETest to China

Wren Laboratories’ NETest leverages mRNA and Artificial Intelligence to create highly accurate, personalized neuroendocrine cancer diagnostics

Development and validation of a Multigenomic Liquid Biopsy (PROSTest) for Prostate Cancer Detection

Evaluation of a novel transcriptomic tumor signature (PROSTest) as response biomarker for 177Lu-PSMA therapy in advanced prostate cancer

‘Breakthrough’ in prostate cancer testing here

Men as young as 40 prompted to test for prostate disease

Taking a Systems Biology Approach to Find a New Pancreatic Cancer Target

Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumors

New Multi-Gene Liquid Biopsy Biomarker for Prostate Cancer

Covid-19 Saliva Test superior to nasal swab

Branford-invented Covid-19 Saliva Test Available

Blood test predicts success of neuroendocrine cancer therapy

Wren Covid-19 Test receives FDA EUA for ages 5+

The future of long-term COVID-19 testing is now

The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors

Branford lab gets FDA emergency authorization for coronavirus saliva test for kids 5 and up

Branford laboratory launches saliva-based COVID-19 tests

NETest Biomarker a Predictor of Tumor Recurrence, Cost Savings